Actinogen Medical Limited · ASX:ACW
Actinogen Medical — Australian Microcap Investment Conference 2018
19 slides from Actinogen Medical's conference presentation, Oct 17, 2018
Slide 1: Australian Microcap Investment Conference
Australian Microcap Investment Conference A novel approach to treating cognitive impairment and Alzheimer’s disease Dr. Bill Ketelbey: CEO & Managing Director October 2018
Slide 2: Key investment highlights
Key investment highlights Actinogen is developing innovative treatments for cognitive impairment associated with neurodegenerative and metabolic diseases, with an initial focus on Alzheimer‘s disease Novel compound Xanamem, lead compound, validated by independent research on the cortisol hypothesis
Slide 3: Human pilot studies validate the cortisol hypothesis
Human pilot studies validate the cortisol hypothesis Two completed pilot studies that indicated inhibiting cortisol production in the brain improves cognitive function in healthy elderly men and subjects with Type 2 diabetes Verbal fluency: Study 11 Verbal memory: Study 22 P=0.006 P=0.005 Placebo 40
Slide 4: Efficacy underpinned by animal model
Efficacy underpinned by animal model Significant and rapid symptomatic and disease modifying effects demonstrated with significant improvement in cognition within one month, continuing out to 41 weeks Cognition: 28 days treatment Amyloid clearance: 28 days treatment Latency to enter dark compartment
Slide 5: What is Xanamem
What is Xanamem Actinogen‘s lead compound, Xanamem, is a novel drug designed to inhibit the production of cortisol in the brain, with the potential to treat cognitive impairment and Alzheimer‘s disease Well researched Over 15 years of R&D completed, with A$40m invested to date Well tolerated Dosed >
Slide 6: Mechanism of action
Mechanism of action Xanamem inhibits the activity of the 11β-HSD1 enzyme, reducing the production of cortisol in the brain Overview Xanamem is targeting diseases with possible cortisol induced cognitive impairment Alzheimer's disease (key focus) Diabetes Depression Parkinson’s disease Schi
Slide 7: Initial strategic focus underpinned by medical research
Initial strategic focus underpinned by medical research A growing body of medical literature supports the association between cortisol and Alzheimer‘s disease Raised cortisol associated with Alzheimer’s disease1 Supported by growing body of medical literature Many studies support the association 0.8
Slide 8: XanADu Phase II clinical trial
XanADu Phase II clinical trial Double-blind, randomised, placebo-controlled study to assess the efficacy and safety of Xanamem in subjects with mild Alzheimer's disease1 Xanamem treatment course 174 patients with mild Alzheimer’s 12 weeks disease (166 enrolled; >111 completed)2 Trial conducted at 25
Slide 9: Interim analysis
Interim analysis Positive recommendations from the DSMB1 reflect confidence in the safety of the drug and the design of the XanADu study. Supports the broader development of Xanamem First DSMB review Second DSMB review Third DSMB review (23 May 2018) (22 August 2018) Evaluation of 50 Evaluation
Slide 10: Additional Xanamem studies
Additional Xanamem studies Actinogen is focused on completing key additional studies to enhance the Xanamem data set Target occupancy study Higher dose safety study Further safety / toxicology studies Aims to accurately demonstrate the To expand the safety data-set for To allow for longer treatment
Slide 11: Other potential indications
Other potential indications Secondary focus is on developing the use of Xanamem in other indications to optimise shareholder value Overview Possible target indications Multiple potential target indications beyond Alzheimer’s represent significant market Diabetes Depression expansion opportunities Gr
Slide 12: Market dynamics of Alzheimer's disease
Market dynamics of Alzheimer’s disease Presents a compelling commercial opportunity for Actinogen to target initially Substantial target market with significant upside1 Underpinned by favourable market dynamics Cortisol-high, Targeting large addressable markets (US, EU5, JP) Subjective Cognitive a
Slide 13: Big Pharma interest
Big Pharma interest Global Big Pharma demonstrating strong M&A interest in acquiring or partnering with companies and licensing assets with Alzheimer’s disease as the lead/key indication Deal value 3,340 3,500 (US$m) Deal value (US$m) 1,200 Upfront (US$m) 1,119 1,000 825 710 725 500 509 526 225 Bidd
Slide 14: Board of Directors
Board of Directors Commercially experienced and globally recognised leadership team with decades of experience in drug development and biotech investment Dr. Geoff Dr. Bill Dr. Jason Dr. George Brooke Ketelbey Loveridge Morstyn Chairman CEO & MD Non-executive Non-executive director director 30+ ye
Slide 15: Advisory Boards
Advisory Boards World’s premier academics involved in the development of Xanamem and as a novel treatment for Alzheimer’s disease XanamemTM Clinical Advisory Board Scientific Advisory Board Positions Xanamem at the forefront of Combining deep understanding of cortisol, Alzheimer’s drug development 1
Slide 16: Upcoming catalysts
Upcoming catalysts Significant upcoming milestones across 2018/19 4Q CY2018 1Q CY2019 2Q CY2019 Phase II clinical trial Milestones Last patient screened Last patient enrolled Release top line results Study duration Target occupancy Study (human) Milestones Study initiated Results release Study durat
Slide 17: Key investment highlights
Key investment highlights Actinogen is developing innovative treatments for cognitive impairment associated with neurodegenerative and metabolic diseases, with an initial focus on Alzheimer‘s disease Novel compound Xanamem, lead compound, validated by independent research on the cortisol hypothesis
Slide 18: Dr. Bill Ketelbey: CEO & Managing Director
Dr. Bill Ketelbey: CEO & Managing Director P: +61 2 8694 7401 E: [email protected]
Slide 19: Disclaimer
Disclaimer This presentation has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to mak
Actinogen Medical — Australian Microcap Investment Conference 2018 on 6ix